New numbers on federal drug spending may say something about prescribing patterns for Medicare patients. Perhaps too many scripts for branded Nexium, when a generic stomach acid reducer might do, for instance.
Is momentum growing behind the idea of Medicare taking a harder line on drug prices? Not in the pharma industry, that's for sure. But a new Inspector General's report adds some numbers to the argument, and as the New York Times reports, the government's precision medicine initiative might just push the issue.
The elimination of the Medicare Sustained Growth Rate formula that threatened large Medicare reimbursement cuts to doctors on an annual basis is the most significant entitlement reform achieved by the new Congress.
Industry watchers knew Medicare would be shelling out a whole lot more on hepatitis C treatments last year, thanks to new-and-improved drugs. But just how much more did it cough up?
The former owner, president and manager of Miami, FL-based Quick Solutions Medical Supplies, Angel Mirabal, has pleaded guilty to healthcare fraud charges, according to a statement from the U.S. Department of Justice.
Flush with success in negotiating discounts for hepatitis C drugs, payers are promising to strong-arm drugmakers in other treatment classes, too--cholesterol and cancer, for instance. They'll have more than one oncologist on their sides: A top doctor at the MD Anderson Cancer Center, fed up with cancer drug prices, plans a social media protest.
AdvaMed CEO Stephen Ubl said the med tech innovation ecosystem is "fraying" at a news conference unveiling the trade association's 2015 Innovation Agenda to fix the ills of the industry.
Medtronic is shelling out $2.8 million to resolve allegations that it coerced doctors to submit false claims to Medicare for its implantable neurostimulation devices, casting a dark cloud over the company weeks after it finalized its merger with Covidien.
As the med tech industry homes in on next-generation devices for peripheral artery disease, medical experts are questioning the necessity of procedures to treat the disease, pointing to large Medicare payments made to physicians performing the operations.
GenomeDx Biosciences bagged Medicare coverage for its postoperative prostate cancer diagnostic, putting its test in the hands of more patients and helping the company gain ground in a crowded market.